A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017

October 16, 2017




The protease inhibitor (PI) darunavir (Prezista) was first approved in the U.S. in 2006, and it is often boosted with ritonavir (Norvir) or cobicistat (Tybost) to maximize its effect. Now, the drug is being investigated as a coformulated, single-tablet combination alongside cobicistat, emtricitabine (FTC, Emtriva) and tenofovir alafenamide (TAF, Vemlidy), and known by the abbreviation D/C/F/TAF. In the Phase III EMERALD trial, from which the latest data were presented on Oct. 6 by Joseph Eron, M.D., a professor of medicine at the University of North Carolina School of Medicine, people who switched to D/C/F/TAF from an already-suppressive regimen consisting of emtricitabine/tenofovir disoproxil fumarate (Truvada or FTC/TDF) plus a boosted protease inhibitor had non-inferior outcomes at week 48.

The primary objective of the trial was to gauge the non-inferiority of D/C/F/TAF versus a control regimen by measuring the proportion of patients experiencing virologic rebound. Eron noted that one interesting feature of the study design was that patients with prior virologic failure were permitted in the study, which creates a more real-world setting -- a design approach that he said is different than previous studies. Overall, 1,141 people were randomized; of those, 18% were women, 76% were white and 15% had failed a prior non-darunavir-based regimen. Participants switched to D/C/F/TAF saw high rates of suppression (95%), no drug resistance and better bone and renal outcomes.

Image credit: Sylverarts for iStock via Thinkstock.

Related Stories

Top HIV Researcher Hails a Resurgent Antiretroviral Pipeline
Ignorance About PrEP Is Common Among Health Care Providers, Studies Suggest
Long-Acting HIV Treatment: 5 Myths and Realities

This article was provided by It is a part of the publication IDWeek 2017.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.